Bayer AG (BAYN.DE) closed €38.32 on 06 Jan 2026: heavy 4.00M volume, watch pipeline
Bayer AG (BAYN.DE) closed €38.32 on XETRA in Germany on 06 Jan 2026, making it one of the day’s most active names with 4,000,960 shares traded. BAYN.DE stock jumped 0.37 or 0.97% intraday as investors digested pipeline news and legal headlines. We open with price, volume and context because those three metrics drove today’s most active status and set the near-term trading tone.
BAYN.DE stock: Market action and liquidity (Most Active)
BAYN.DE stock finished the session at €38.32 on XETRA with 4,000,960 shares changing hands, 1.50 times average volume, confirming high liquidity and active interest.
BAYN.DE stock: What moved the price today
Share gains followed company updates and litigation developments, notably pre-conference investor positioning ahead of the J.P. Morgan Healthcare event and renewed legal attention in the U.S., which traders priced into the session.
BAYN.DE stock: Fundamentals and valuation snapshot
Bayer reports a market cap near €37.53B, price-to-sales 0.81, price-to-book 1.26, and negative trailing EPS -0.20 with a reported PE of -191.00, highlighting a mixed valuation profile driven by cash flow strength and legacy liabilities.
BAYN.DE stock: Cash flow, leverage and profitability metrics
Free cash flow yield sits near 10.56%, debt-to-equity is 1.34, interest coverage about 2.91, and operating margin 11.61%, showing solid cash generation but elevated leverage that keeps risk premiums high.
BAYN.DE stock: Technicals and short-term trading signals
Technicals show RSI 67.88 (near overbought), ADX 41.59 indicating a strong trend, and Bollinger upper band €38.61, suggesting momentum favors continuation but with narrowing room for upside.
BAYN.DE stock: Catalysts, news flow and risks
Near-term catalysts include Bayer’s presentation at the J.P. Morgan Healthcare Conference and Phase II/III trial milestones, balanced against U.S. litigation outcomes and regulatory reviews that remain major risk drivers. Business Wire and Nasdaq reported recent Bayer updates and market commentary.
Final Thoughts
Bayer AG (BAYN.DE) closed €38.32 on XETRA on 06 Jan 2026, with active volume 4,000,960 and a clear split between robust cash flow and legacy legal risk. Fundamental ratios show low P/S 0.81 and attractive free cash flow yield 10.56%, while leverage (debt-to-equity 1.34) and negative trailing EPS -0.20 keep valuation discounts in place. Meyka AI rates BAYN.DE with a score of 70.84 out of 100 (Grade B+, Suggestion: BUY). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a monthly price of €39.39 (implied upside 2.79% vs €38.32), quarterly €31.60 (implied downside -17.54%) and yearly €7.35 (large downside driven by conservative long-term scenarios); forecasts are model-based projections and not guarantees. For active traders, the stock’s volume, RSI and conference catalysts justify short-term attention; for longer-term investors, watch trial readouts, litigation rulings, and cash flow trends before adding exposure. For the Meyka stock page and live tools, see our BAYN.DE coverage on Meyka: BAYN.DE on Meyka.
FAQs
BAYN.DE stock rose after pipeline news and pre-conference positioning ahead of the J.P. Morgan Healthcare event, combined with active trading on U.S. litigation developments.
Valuation is mixed: price-to-sales **0.81** and price-to-book **1.26** look reasonable, but negative trailing EPS **-0.20** and high leverage push some analysts to apply a discount.
Meyka AI rates BAYN.DE **70.84/100** (Grade B+, Suggestion: BUY), balancing strong cash flow metrics against legal and leverage risks; this is informational, not investment advice.
Key catalysts are J.P. Morgan conference updates, Phase II/III trial readouts, and major litigation rulings in the U.S., all of which can drive volatility and re-rate the stock.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
